First Wave BioPharma, Inc.

First Wave BioPharma, Inc. (formerly AzurRx BioPharma) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

First Wave is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. 

Nasdaq: FWBI
IR Website:
Headquarters: Boca Raton, FL

Content provided by First Wave BioPharma on 2-14-22.


The First Wave BioPharma management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.


Press Releases

Investor Presentation

Stock Chart (Intraday)

Stock Chart (Historical)

Stock Detail

Leadership In Commercialization

The Gastroenterology Market

First Wave Pipeline




SEC Filings

Management Overview

Risks & Disclosures